Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Tennessee: - Bristol Regional Medical Center — Bristol, Tennessee
- Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
- Ballad Health Cancer Care - Kingsport — Kingsport, Tennessee
- Wellmont Holston Valley Hospital and Medical Center — Kingsport, Tennessee
- Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in Tennessee: - Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
- Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Tennessee: - T C Thompson Children's Hospital — Chattanooga, Tennessee
- East Tennessee Childrens Hospital — Knoxville, Tennessee
- The Children's Hospital at TriStar Centennial — Nashville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 3 Recruiting Industry
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutatio…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06852222
Sites in Tennessee: - University of Tennessee — Knoxville, Tennessee
- Vanderbilt Ingram Cancer Center — Nashville, Tennessee
Phase 3 Recruiting Industry
Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T…
Sponsor: Ascentage Pharma Group Inc.
NCT ID: NCT06423911
Sites in Tennessee: - Ascentage Investigative Site #1063 — Chattanooga, Tennessee
- Ascentage Investigative Site #1089 — Nashville, Tennessee
Phase 3 Recruiting Academic/Other
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…
Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
- Monroe Carell Jr. Children's Hospital at Vanderbilt — Nashville, Tennessee
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). …
Sponsor: BeOne Medicines
NCT ID: NCT06943872
Sites in Tennessee: - Tennessee Oncology Greco Hainsworth Centers For Research Chattanooga — Chattanooga, Tennessee
- Tennessee Oncology — Nashville, Tennessee
Phase 3 Recruiting Industry
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Sponsor: Quetzal Therapeutics
NCT ID: NCT07504458
Sites in Tennessee: - Quetzal Site 12 — Nashville, Tennessee
Phase 2 Recruiting NIH
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in Tennessee: - Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
- University of Tennessee - Knoxville — Knoxville, Tennessee
- Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Tennessee: - East Tennessee Childrens Hospital — Knoxville, Tennessee
- The Children's Hospital at TriStar Centennial — Nashville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Tennessee: - Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
- University of Tennessee - Knoxville — Knoxville, Tennessee
- Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younge…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06672146
Sites in Tennessee: - University of Tennessee - Knoxville — Knoxville, Tennessee
Phase 1, Phase 2 Recruiting Industry
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in Tennessee: - TriStar Centennial Medical Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Sponsor: BeOne Medicines
NCT ID: NCT05006716
Sites in Tennessee: - Tennesse Oncology Chattanooga Downtown — Chattanooga, Tennessee
- Tennessee Oncology, Pllc Nashville — Nashville, Tennessee
Phase 2 Recruiting Industry
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibito…
Sponsor: Nurix Therapeutics, Inc.
NCT ID: NCT07221500
Sites in Tennessee: - SCRI Oncology Partners — Nashville, Tennessee
Phase 2 Recruiting Industry
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of tre…
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT06588478
Sites in Tennessee: - The West Clinic, PLLC dba West Cancer Center — Germantown, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate t…
Sponsor: Cellectis S.A.
NCT ID: NCT04150497
Sites in Tennessee: - Sarah Cannon - HCA Research Institute — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Sponsor: Vironexis Biotherapeutics Inc.
NCT ID: NCT06533579
Sites in Tennessee: - TriStar BMT — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid mali…
Sponsor: AVM Biotechnology Inc
NCT ID: NCT04329728
Sites in Tennessee: - Baptist Clinical Research Institute — Memphis, Tennessee
Phase 1, Phase 2 Recruiting Industry
The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed/refractory T-ALL/LBL patients. Participants with relapsed/refractory T-ALL/LBL over the age of 1 year will be eligible to participate…
Sponsor: Imviva Bio
NCT ID: NCT07070219
Sites in Tennessee: - Sarah Cannon Research Insitute — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).
Sponsor: AstraZeneca
NCT ID: NCT07109219
Sites in Tennessee: - Research Site — Franklin, Tennessee
Phase 2 Recruiting Academic/Other
This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors. The primary outcome is the change in mus…
Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT05194397
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 2 Recruiting Academic/Other
CAR19PK is a research study evaluating the use of lymphodepleting chemotherapy and chimeric antigen receptor (CAR) T cell therapy, a type of cellular therapy, for the treatment of refractory and/or relapsed leukemia. For this type of thera…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT06847269
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 2 Recruiting Academic/Other
This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphobl…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT07228741
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 1 Recruiting Industry
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose c…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT06001788
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee